Your browser doesn't support javascript.
loading
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva, Marc; Chepeha, Douglas; Araujo, Daniel V; Diaz-Mejia, J Javier; Olson, Peter; Prawira, Amy; Spreafico, Anna; Bratman, Scott V; Shek, Tina; de Almeida, John; R Hansen, Aaron; Hope, Andrew; Goldstein, David; Weinreb, Ilan; Smith, Stephen; Perez-Ordoñez, Bayardo; Irish, Jonathan; Torti, Dax; Bruce, Jeffrey P; Wang, Ben X; Fortuna, Anthony; Pugh, Trevor J; Der-Torossian, Hirak; Shazer, Ronald; Attanasio, Nickolas; Au, Qingyan; Tin, Antony; Feeney, Jordan; Sethi, Himanshu; Aleshin, Alexey; Chen, Isan; Siu, Lillian.
Affiliation
  • Oliva M; Department of Medical Oncology, Institut Catala d' Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Chepeha D; Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Araujo DV; Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Diaz-Mejia JJ; Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Olson P; Division of Medical Oncology, Hospital de Base São Jose do Rio Preto, Sao Paulo, Brazil.
  • Prawira A; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Spreafico A; Department of Research, Mirati Therapeutics, San Diego, California, USA.
  • Bratman SV; Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital, Sidney, New South Wales, Australia.
  • Shek T; Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • de Almeida J; Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
  • R Hansen A; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Hope A; Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
  • Goldstein D; Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Weinreb I; Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Smith S; Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
  • Perez-Ordoñez B; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Irish J; Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Torti D; Department of Pathology, University Health Network, Toronto, Ontario, Canada.
  • Bruce JP; Department of Pathology, University Health Network, Toronto, Ontario, Canada.
  • Wang BX; Department of Pathology, University Health Network, Toronto, Ontario, Canada.
  • Fortuna A; Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Pugh TJ; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Der-Torossian H; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Shazer R; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Attanasio N; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Au Q; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Tin A; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Feeney J; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Sethi H; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Aleshin A; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Chen I; Clinical Development, Mirati Therapeutics, San Diego, California, USA.
  • Siu L; Clinical Development, Mirati Therapeutics, San Diego, California, USA.
J Immunother Cancer ; 9(10)2021 10.
Article in En | MEDLINE | ID: mdl-34599023
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Mouth Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Nivolumab / Anilides Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Mouth Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Nivolumab / Anilides Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Type: Article Affiliation country: Spain